<DOC>
	<DOCNO>NCT00082095</DOCNO>
	<brief_summary>The main purpose study compare treatment either pegylated liposomal doxorubicin capecitabine first line chemotherapy metastatic breast cancer woman 60 year old .</brief_summary>
	<brief_title>To Compare Treatment With Doxorubicin Capecitabine Metastatic Breast Cancer Women 60 Years Older</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , randomize ( study medication assign chance ) , multicenter study compare pegylated liposomal doxorubicin ( PLD ) capecitabine first line chemotherapy metastatic breast cancer woman 60 year old . The study consist screen Phase ( 14 day prior treatment ) , treatment phase ( 1 year ) , post-treatment follow-up phase . The planned duration treatment 1 year absence disease progression unacceptable toxicity . Approximately 300 patient enrol randomly assign receive 1 2 treatment group ( PLD capecitabine ) . Safety evaluation consist vital sign examination , physical examination , incidence severity adverse event , laboratory test find follow throughout study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Clinically pathologically proven metastatic breast cancer Eastern Cooperative Oncology Group performance status 02 Adequate bone marrow , renal liver function within normal limit Left ventricular ejection fraction 45 % measure multiple gated acquisition scan echocardiogram within 6 week randomization Prior chemotherapy metastatic disease ( hormonal chemotherapy adjuvant set hormonal therapy metastatic setting allow ) Prior treatment capecitabine pegylated liposomal doxorubicin adjuvant setting ( prior anthracyclines certain dose limit allow ) Evidence brain metastasis unless previously treat asymptomatic 3 month great History cardiac disease New York Heart Association Class II great clinical evidence congestive heart failure Anthracycline resistant disease ( locally recurrent metastatic disease adjuvant anthracycline therapy relapse le 18 month therapy completion )</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Pegylated Liposomal Doxorubicin</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>DOXIL</keyword>
	<keyword>Xeloda</keyword>
</DOC>